The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week

Biotech stocks were seen consolidating last week after advancing in the previous week. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) reached a 52-week high of 121.16 Monday, although it has come off this level since then.

The week saw huge moves in reaction to presentations at the American Society of Hematology annual meeting. A few M&A announcements were made, including Merck & Co., Inc.'s (NYSE: MRK) deal to buy ArQule, Inc. (NASDAQ: ARQL) and Sanofi SA's (NASDAQ: SNY) proposed purchase of Synthorx Inc (NASDAQ: THOR).